A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects

NCT00000795 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: HIV-1 Peptide Immunogen, Multivalent

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)